The testing of MET Exon 14 skipping mutations was performed centrally on circulating free DNA (cfDNA) obtained from plasma (liquid biopsy), with the use of the NGS panel Guardant360 or by evaluating RNA that had been obtained from fresh or archival (formalin-fixed, paraffin-embedded) tumor biopsy tissue with the use of the Oncomine Focus Assay. The gene discussed is MET; the disease is neoplasm.